Cardiovascular effects of antidiabetic drugs.

• Autores: A.M.S. Soerensen, B. M. Christensen
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 54, Nº. 9, 2018, págs. 547-560
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Type 2 diabetes mellitus is a common and severe chronic metabolic disease, which confers increased risk of cardiovascular disease and mortality. During the last decade a large number of new drugs within the classes dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP-4Is), glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 (SGLT-2) inhibitors (SGLT-2Is) have been developed and tested in nine large-scale cardiovascular outcome trials (CVOTs). Here we review the evidence behind antihyperglycemic treatment of patients with type 2 diabetes with a particular focus on compiling and summarizing the evidence of hard clinical endpoints stemming from these large CVOTs.